Sealife Pharma GmbH is an innovative drug development company focused on delivering new
first in class antibiotics derived from the chemical diversity of marine fungi (also known as
microbes or bugs from the sea).
Sealife has fully equipped synthetic and analytical chemistry as well as microbial and cell biology laboratories and is based in Austria at the Technopark 1, Tulln.
Besides developing novel antibiotics to fight multi-drug resistant infections, Sealife also provides CRO
services to the pharmaceutical sector.
SeaLife Pharma GmbH is proud to announce that it has partnered in the EU FP7 funded project named Macumba - Marine Microorganisms: Cultivation Methods for Improving their Biotechnological Applications, with a total funding of 12 Mio € and 23 partners from 11 nations.
38-year old marine biologist Alexander Pretsch has made it his startup’s mission to find a drug against problematic bacteria, such as MRSA, Streptococcus or Enterococci – a mission whose goal is becoming more and more attainable ...
Sealife is pleased to announce that it has become a partner in the PharmaSea project funded by the European Union under its FP7 program. This project focuses on bio-discovery research, development and commercialization of new substances from marine organisms. Its primary goal is to collect marine samples ...